David Michael Hanna
David Hanna is a senior counsel in the Life Sciences Group in the Litigation Department, where he focuses on biologic drug patent and Hatch-Waxman patent litigation. David’s biologics drug patent litigation experience includes litigating matters relating to Avastin® (bevacizumab) and Herceptin® (trastuzumab).
David has represented both patentees and generic filers in Hatch-Waxman litigation. He has litigated matters relating to Imbruvica® (ibrutinib), Xarelto® (rivaroxaban), Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).
David has also represented a major pharmaceutical company in product liability matters relating to Viread®, Truvada®, Atripla®, and other antiviral medications containing tenofovir disoproxil fumarate (“TDF”).
In the top law firm directory The Legal 500 US, a client recommended David, noting his client service for being “super responsive and very detail oriented.”
No Posts Found for David Michael Hanna
Sorry, but the content from this archive cannot be found. Please try searching below, or use the navigation menu above.